European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
Go back to European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors| Pfizer Inc. (NYSE: PFE) | Delayed: 24.88 -0.2 (0.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $24.99 | 52 Week Low | $28.25 | |||
| Day High | $25.24 | P/E | 15.08 | |||
| Day Low | $24.78 | EPS | $1.65 | |||
| Volume | 30,146,679 | |||||
